Stock Market Recap: Astrazeneca plc ADR (AZN) Concludes at 78.59, a 0.60 Surge/Decline

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

After finishing at $78.12 in the prior trading day, Astrazeneca plc ADR (NASDAQ: AZN) closed at $78.59, up 0.60%. In other words, the price has increased by $0.60 from its previous closing price. On the day, 2.67 million shares were traded. AZN stock price reached its highest trading level at $78.69 during the session, while it also had its lowest trading level at $77.92.

Ratios:

Our goal is to gain a better understanding of AZN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.73. For the most recent quarter (mrq), Quick Ratio is recorded 0.70 and its Current Ratio is at 0.89. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.75.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on May 30, 2024, initiated with a Buy rating and assigned the stock a target price of $97.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AZN now has a Market Capitalization of 243671416832 and an Enterprise Value of 148464910336. As of this moment, Astrazeneca’s Price-to-Earnings (P/E) ratio for their current fiscal year is 38.73, and their Forward P/E ratio for the next fiscal year is 16.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.12 while its Price-to-Book (P/B) ratio in mrq is 6.22. Its current Enterprise Value per Revenue stands at 3.118 whereas that against EBITDA is 9.395.

Stock Price History:

The Beta on a monthly basis for AZN is 0.47, which has changed by 0.1634345 over the last 52 weeks, in comparison to a change of 0.24125004 over the same period for the S&P500. Over the past 52 weeks, AZN has reached a high of $80.86, while it has fallen to a 52-week low of $60.47. The 50-Day Moving Average of the stock is 0.63%, while the 200-Day Moving Average is calculated to be 13.47%.

Shares Statistics:

The stock has traded on average 4.38M shares per day over the past 3-months and 2853540 shares per day over the last 10 days, according to various share statistics. A total of 3.10B shares are outstanding, with a floating share count of 3.10B. Insiders hold about 0.02% of the company’s shares, while institutions hold 16.02% stake in the company. Shares short for AZN as of 1719532800 were 6410824 with a Short Ratio of 1.46, compared to 1717113600 on 6667770.

Dividends & Splits

In the trailing 12 months, AZN’s forward annual dividend rate was 2.9, compared to 1.45 this year. Against a Trailing Annual Dividend Yield of 0.037122376The stock’s 5-year Average Dividend Yield is 2.44. The current Payout Ratio is 73.87% for AZN, which recently paid a dividend on 2024-02-22 with an ex-dividend date of 1708560000. Stock splits for the company last occurred on 2015-07-27 when the company split stock in a 2:1 ratio.

Most Popular